Sorrento Therapeutics, Inc. announced that it has formed an exclusive partnership with the Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies. Under the agreement, Sorrento will sponsor preclinical and clinical research & development programs focused on NK biology as well as adoptive NK cell therapies and, in return, obtain full rights to the resulting discoveries and developments. The research will be performed at KI, but there will also be an active research exchange with Sorrento R&D in San Diego.

A joint steering committee with members from both Sorrento and KI will guide the program activities.